Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

Market Cap	4.66B
Revenue (ttm)	1.04B
Net Income (ttm)	35.69M
Shares Out	399.40M
EPS (ttm)	0.09
PE Ratio	130.24
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,000
Average Volume	254,500
Open	11.56
Previous Close	11.68
Day's Range	11.54 - 12.12
52-Week Range	5.60 - 17.30
Beta	0.06
RSI	43.09
Earnings Date	May 28, 2025

About HKG:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 1,117
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2315

Financial Performance

Financial numbers in CNY